StreetInsider.com News Articles

Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform

Thu, 23 Jul 2026 06:06:50 -0400

(Updated - July 23, 2026 6:06 AM EDT)

Oppenheimer analyst Leland Gershell initiated Palisade Bio Inc. (NASDAQ: PALI) at Outperform with a price target of $8.00.

The analyst commented: "We believe PALI offers investors an attractive way to participate in the large/growing inflammatory bowel disease (IBD) space as the company's therapeutic development programs—whose approach is orthogonal to those of ABVX and EQ and backed by compelling early clinical results—move toward their first Phase 2 readout next year. We believe PALI‑2108’s appeal lies in its potential for biologic-like early symptom improvement paired with a once-daily oral profile better suited for long-term maintenance—a profile

Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform

Thu, 23 Jul 2026 06:06:50 -0400

(Updated - July 23, 2026 6:06 AM EDT)

Oppenheimer analyst Leland Gershell initiated Palisade Bio Inc. (NASDAQ: PALI) at Outperform with a price target of $8.00.

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260710/26758186.html

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260710/26758186.html

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts.

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Baltera Robert Jr.

Wed, 08 Jul 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748611.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Baltera Robert Jr.

Wed, 08 Jul 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748611.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Jones Mitchell Lawrence

Wed, 08 Jul 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260708/26748599.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Jones Mitchell Lawrence

Wed, 08 Jul 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260708/26748599.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Finley John David

Wed, 08 Jul 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260708/26748593.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Finley John David

Wed, 08 Jul 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260708/26748593.html

Form 144 PALISADE BIO, INC. Filed by: Jones Mitchell Lawrence

Tue, 07 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260707/26742710.html

Form 144 PALISADE BIO, INC. Filed by: Jones Mitchell Lawrence

Tue, 07 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260707/26742710.html

Form 144 PALISADE BIO, INC. Filed by: Finley John David

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742528.html

Form 144 PALISADE BIO, INC. Filed by: Finley John David

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742528.html

Form 4 PALISADE BIO, INC. For: Jul 01 Filed by: Baltera Robert Jr.

Mon, 06 Jul 2026 19:48:00 -0400

si-local-file:///var/storage/secattach/20260706/26737095.html

Form 4 PALISADE BIO, INC. For: Jul 01 Filed by: Baltera Robert Jr.

Mon, 06 Jul 2026 19:48:00 -0400

si-local-file:///var/storage/secattach/20260706/26737095.html

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Tue, 30 Jun 2026 06:45:41 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $7.00 price target on Palisade Bio Inc. (NASDAQ: PALI).

The analyst commented: "Palisade Bio announced FDA IND clearance for the global Phase 2 ASCENTRA-UC trial of PALI-2108 in ulcerative colitis (UC), with enrollment expected to begin in 2H26 and primary efficacy data expected in 2H27. The ASCENTRA-UC trial is slated to enroll up to 204 moderate-to-severe UC patients randomized to once-daily 15mg PALI-2108, 30mg PALI-2108, or placebo for 12 weeks, with clinical remission by modified Mayo Score as the primary endpoint and a 36-week maintenance period to assess durability through

Palisade Bio gets FDA clearance to begin Phase 2 UC drug trial

Mon, 29 Jun 2026 08:30:53 -0400

Palisade Bio, Inc. (NASDAQ: PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PALI-2108, an oral PDE4 inhibitor prodrug candidate for inflammatory bowel disease, allowing the company to proceed with a global Phase 2 clinical trial in ulcerative colitis.

The trial, called ASCENTRA-UC, is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study expected to enroll approximately 204 patients with moderately to severely active ulcerative colitis across sites in North America and Europe. The study will evaluate two once-daily dose levels of PALI-2108, 15 mg and 30 mg, compared with placebo.

The primary endpoint is clinical

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Denver, CO, June 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio